NYSE · CIK 0001919246
PTHS Pelthos Therapeutics Inc.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $20.50 on Oct 9, 2026, +13% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
-$45k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$45k by 3 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
PTHSOct 9, 2026 · close 20.50
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Pelthos Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Ezra M Friedberg director sell | $12k 558 shares | -1% | - | |
| 10Weak | Peter Greenleaf director sell | $17k 797 shares | -3% | - | |
| 10Weak | Matthew Pauls director sell | $17k 786 shares | -5% | - |
Transactions
The last 41 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Peter Greenleaf director | SOpen-market sale Common Stock10b5-1 | -797 | $21.17 | $17k | 23,087 | 6 d ago |
| Oct 2, 2026 | Matthew Pauls director | SOpen-market sale Common Stock10b5-1 | -786 | $21.00 | $17k | 13,578 | 6 d ago |
| Oct 2, 2026 | Ezra M Friedberg director | SOpen-market sale Common Stock10b5-1 | -558 | $20.72 | $12k | 80,484 | 6 d ago |
| Jul 2, 2025 | Scott M. Plesha CEO and President | AGrant or award Restricted Stock Unitsderivative | +83,678 | - | - | 83,678 | Jul 23, 2025 |
| Jul 2, 2025 | Scott M. Plesha CEO and President | AGrant or award Stock Optionderivative | +255,000 | - | - | 255,000 | Jul 23, 2025 |
| Jul 2, 2025 | Sai Rangarao Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +30,518 | - | - | 30,518 | Jul 21, 2025 |
| Jul 2, 2025 | Sai Rangarao Chief Commercial Officer | AGrant or award Stock Optionderivative | +93,000 | - | - | 93,000 | Jul 21, 2025 |
| Jul 2, 2025 | Todd C Davis director | AGrant or award Restricted Stock Unitsderivative | +19,108 | - | - | 36,969 | Jul 7, 2025 |
| Jul 2, 2025 | Knuettel Francis II CFO, Treas & Secty | AGrant or award Restricted Stock Unitsderivative | +33,472 | - | - | 33,472 | Jul 7, 2025 |
| Jul 2, 2025 | Richard B Baxter director | AGrant or award Restricted Stock Unitsderivative | +19,108 | - | - | 19,108 | Jul 7, 2025 |
| Jul 2, 2025 | Ezra M Friedberg director | AGrant or award Restricted Stock Unitsderivative | +19,108 | - | - | 28,012 | Jul 7, 2025 |
| Jul 2, 2025 | Peter Greenleaf director | AGrant or award Restricted Stock Unitsderivative | +25,478 | - | - | 25,478 | Jul 7, 2025 |
| Jul 2, 2025 | Richard Malamut director | AGrant or award Restricted Stock Unitsderivative | +19,108 | - | - | 28,012 | Jul 7, 2025 |
| Jul 2, 2025 | Matthew Pauls director | AGrant or award Restricted Stock Unitsderivative | +25,478 | - | - | 25,478 | Jul 7, 2025 |
| Jul 2, 2025 | Todd C Davis director | AGrant or award Stock Optionderivative | +58,230 | - | - | 58,230 | Jul 7, 2025 |
| Jul 2, 2025 | Richard B Baxter director | AGrant or award Stock Optionderivative | +58,230 | - | - | 58,230 | Jul 7, 2025 |
| Jul 2, 2025 | Matthew Pauls director | AGrant or award Stock Optionderivative | +77,640 | - | - | 77,640 | Jul 7, 2025 |
| Jul 2, 2025 | Richard Malamut director | AGrant or award Stock Optionderivative | +58,230 | - | - | 58,230 | Jul 7, 2025 |
| Jul 2, 2025 | Peter Greenleaf director | AGrant or award Stock Optionderivative | +77,640 | - | - | 77,640 | Jul 7, 2025 |
| Jul 2, 2025 | Ezra M Friedberg director | AGrant or award Stock Optionderivative | +58,230 | - | - | 58,230 | Jul 7, 2025 |
| Jul 2, 2025 | Knuettel Francis II CFO, Treas & Secty | AGrant or award Stock Optionderivative | +102,000 | - | - | 145,074 | Jul 7, 2025 |
| Jul 1, 2025 | Todd C Davis director, owner | CConversion Common Stockindirect: By Ligand Pharmaceuticals Incorporated | +1,500,000 | $10.00 | $15M | 1,500,000 | Jul 3, 2025 |
| Jul 1, 2025 | Knuettel Francis II Chief Financial Officer | CConversion Common Stockindirect: By Camden Capital LLC | +10,000 | $10.00 | $100k | 10,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | CConversion Common Stockindirect: By Balmoral Financial Group LLC | +40,000 | $10.00 | $400k | 40,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ligand Pharmaceuticals Inc owner | CConversion Common Stock | +1,500,000 | $10.00 | $15M | 1,500,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | CConversion Common Stockindirect: By Key Recovery Group LLC | +40,000 | $10.00 | $400k | 40,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ligand Pharmaceuticals Inc owner | CConversion Series A Convertible Preferred Stockderivative | -15,000 | $0.00 | $0 | 3,000 | Jul 3, 2025 |
| Jul 1, 2025 | Todd C Davis director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000 | $0.00 | $0 | 3,000 | Jul 3, 2025 |
| Jul 1, 2025 | Knuettel Francis II Chief Financial Officer | JOther Series A Convertible Preferred Stockderivativeindirect: See footnote | +10,000 | $0.00 | $0 | 10,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ligand Pharmaceuticals Inc owner | JOther Series A Convertible Preferred Stockderivative | +31,279 | - | - | 34,279 | Jul 3, 2025 |
| Jul 1, 2025 | Todd C Davis director, owner | JOther Series A Convertible Preferred Stockderivativeindirect: See footnote | +31,279 | - | - | 3,127,868 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | POpen-market purchase Series A Convertible Preferred Stockderivativeindirect: By Balmoral Financial Group LLC | +40,000 | $0.00 | $0 | 40,000 | Jul 3, 2025 |
| Jul 1, 2025 | Knuettel Francis II Chief Financial Officer | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -10,000 | $0.00 | $0 | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | POpen-market purchase Series A Convertible Preferred Stockderivativeindirect: By Key Recovery Group LLC | +40,000 | $0.00 | $0 | 40,000 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | CConversion Series A Convertible Preferred Stockderivativeindirect: By Balmoral Financial Group LLC | -40,000 | $0.00 | $0 | 0 | Jul 3, 2025 |
| Jul 1, 2025 | Ezra M Friedberg director | CConversion Series A Convertible Preferred Stockderivativeindirect: By Key Recovery Group LLC | -40,000 | $0.00 | $0 | 0 | Jul 3, 2025 |
| Apr 11, 2025 | Knuettel Francis II CEO, Pres., CFO, Treas & Secty | AGrant or award Stock Optionderivative | +53,988 | - | - | 430,736 | Apr 15, 2025 |
| Apr 11, 2025 | Chia-Lin Simmons director | AGrant or award Stock Optionderivative | +25,000 | - | - | 130,000 | Apr 15, 2025 |
| Nov 13, 2024 | Ezra M Friedberg director | AGrant or award Restricted Stock Unitsderivative | +24,533 | - | - | 634,752 | Nov 15, 2024 |
| Nov 13, 2024 | Richard Malamut director | AGrant or award Restricted Stock Unitsderivative | +24,533 | - | - | 116,098 | Nov 15, 2024 |
| Nov 13, 2024 | Todd C Davis director | AGrant or award Restricted Stock Unitsderivative | +49,605 | - | - | 263,306 | Nov 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Richard B Baxterdirector
- Todd C Davisdirector, ceo, officer, owner
- Knuettel Francis IICFO, Treas & Secty
- Ezra M Friedbergdirector
- Peter Greenleafceo, officer, director
- Ligand Pharmaceuticals Incowner
- Richard Malamutdirector
- Matthew Paulsceo, officer, director
- Scott M. PleshaCEO and President
- Sai RangaraoChief Commercial Officer
- Chia-Lin Simmonsceo, president, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.